Product news

Share this article:
The FDA has approved GlaxoSmithKline's Rotarix (rotavirus vaccine, live, oral) for the prevention of rotavirus gastroenteritis in infants. Rotarix is indicated to offer protection against the most commonly circulating rotavirus types in the US and allow infants to complete the vaccination series by four months of age. The US Centers for Disease Control and Prevention currently recommends that children complete the rotavirus immunization series by six months of age. 
 
Abbott said it has received marketing authorization from the European Commission for a new, lower-strength tablet formulation of HIV protease inhibitor, Kaletra (lopinavir/ritonavir).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions